CEL-SCI (CVM) News Today $2.51 +0.05 (+2.03%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.54 +0.04 (+1.39%) As of 05/23/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CVM Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period CEL-SCI Announces Closing of Public OfferingMay 23 at 4:05 PM | businesswire.comBiggest stock movers Thursday: SNOW, URBN, and moreMay 22 at 8:34 AM | msn.comCEL-SCI plummets 44%, prices $5M stock offeringMay 22 at 8:34 AM | msn.comCEL-SCI Announces Pricing of Public OfferingMay 21, 2025 | businesswire.comCEL-SCI Implements 1-for-30 Stock Split To Support Share PriceMay 21, 2025 | nasdaq.comCEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi ArabiaMay 21, 2025 | finance.yahoo.comCEL-SCI Announces Proposed Public OfferingMay 21, 2025 | businesswire.comCEL-SCI Corporation Announces a 1 for 30 Combination of Common StockMay 20, 2025 | finanznachrichten.deCEL-SCI Announces Combination of Common StockMay 19, 2025 | businesswire.comStockNews.com Begins Coverage on CEL-SCI (NYSE:CVM)May 18, 2025 | americanbankingnews.comCEL-SCI Reports Fiscal Second Quarter 2025 Financial ResultsMay 15, 2025 | finance.yahoo.comCEL-SCI says publication supports strategy to seek early approval for multikineApril 10, 2025 | markets.businessinsider.comNew Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor ResponsesApril 8, 2025 | businesswire.comCEL-SCI publishes new data from Multikine studyMarch 26, 2025 | markets.businessinsider.comCEL-SCI Announces Closing of $2.5 Million OfferingMarch 18, 2025 | finance.yahoo.comCEL-SCI announces pricing of $2.56M common stock offeringMarch 18, 2025 | markets.businessinsider.comCEL-SCI Announces Pricing of $2.5 Million OfferingMarch 17, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 15, 2025 | businesswire.comJournal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD ...March 15, 2025 | businesswire.comCEL-SCI announces neoadjuvant nivolumab plus chemotherapy study publishedMarch 15, 2025 | markets.businessinsider.comCEL-SCI to initiate Multikine cancer trialFebruary 20, 2025 | markets.businessinsider.comCEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer TrialFebruary 20, 2025 | businesswire.comCEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 WeeksFebruary 19, 2025 | finance.yahoo.comCVM: Fiscal Year 2024 ResultsFebruary 11, 2025 | finance.yahoo.comCEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck CancerJanuary 14, 2025 | finance.yahoo.comCEL-SCI (AMEX:CVM) Stock Quotes, Forecast and News SummaryDecember 31, 2024 | benzinga.comWhat's Going On With Cel-Sci Shares Premarket On Monday?December 30, 2024 | benzinga.comCEL-SCI prices $5M public offering at 31c per shareDecember 30, 2024 | markets.businessinsider.comCEL-SCI prices $5 million offeringDecember 30, 2024 | msn.comCel-Sci Stock Slips After Public Offering: Retail's NeutralDecember 30, 2024 | msn.comCEL-SCI Prices Public Offering Of 16.13 Mln Shares At $0.31/shrDecember 29, 2024 | markets.businessinsider.comCEL-SCI Announces Pricing of $5 Million Public OfferingDecember 29, 2024 | businesswire.comCEL-SCI announces common stock offering, no amount givenDecember 27, 2024 | msn.comCEL-SCI Announces Proposed Public Offering of Common StockDecember 27, 2024 | businesswire.comCEL-SCI provides rationale for use of Multikine in head, neck cancer studyDecember 13, 2024 | markets.businessinsider.comCVM: CRO Selected for Registrational TrialDecember 9, 2024 | msn.comU.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025November 7, 2024 | finance.yahoo.com3 Interesting Emerging Growth Stock Ideas From the 2024 Think Equity ConferenceNovember 4, 2024 | investing.comCEL-SCI files to sell 1M shares of common stock for holdersOctober 25, 2024 | markets.businessinsider.comUpstream Bio Inc.October 14, 2024 | money.usnews.comCalcium-mediated effect plays key role in cell disposal, researchers discoverOctober 11, 2024 | msn.comCEL-SCI (NYSE:CVM) Trading Down 3.8% - Here's What HappenedCEL-SCI (NYSE:CVM) Stock Price Down 3.8% - Time to Sell?October 11, 2024 | marketbeat.comCEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck CancerOctober 1, 2024 | finance.yahoo.comCVM Oct 2024 2.000 callSeptember 21, 2024 | ca.finance.yahoo.comCEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 CongressSeptember 10, 2024 | finance.yahoo.comCVM Jan 2025 1.500 callAugust 30, 2024 | ca.finance.yahoo.comCVM Sep 2024 1.500 callAugust 29, 2024 | ca.finance.yahoo.comCVM Oct 2024 1.500 callAugust 29, 2024 | ca.finance.yahoo.comCVM Apr 2025 1.000 putAugust 29, 2024 | ca.finance.yahoo.comCVM: Start Your Engines – FDA Green Lights Confirmatory Registration StudyAugust 28, 2024 | finance.yahoo.com Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address CVM Media Mentions By Week CVM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVM News Sentiment▼-0.010.77▲Average Medical News Sentiment CVM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVM Articles This Week▼91▲CVM Articles Average Week Get CEL-SCI News Delivered to You Automatically Sign up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Sutro Biopharma News Today IGM Biosciences News Today Zura Bio News Today Elutia News Today Vistagen Therapeutics News Today Unicycive Therapeutics News Today InterCure News Today TScan Therapeutics News Today Seres Therapeutics News Today Alto Neuroscience News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CVM) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
